osimertinib
astrazeneca
['nsclc', 'lcsm,(-blcsm)', 'sclc', 'osimertinib']
adjuvant osimertinib provides os benefit in egfr+ stage ib-iiia nsclc #asco23 #asco2023 #lcsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.